Administration de la santé publique : Questions médicales fréquentes
Nom anglais: Public Health Administration
Descriptor UI:D011635
Tree Number:N04.452.794
Termes MeSH sélectionnés :
Engineering
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Administration de la santé publique : Questions médicales les plus fréquentes",
"headline": "Administration de la santé publique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Administration de la santé publique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-23",
"dateModified": "2025-02-17",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Administration de la santé publique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Organisation et administration",
"url": "https://questionsmedicales.fr/mesh/D009934",
"about": {
"@type": "MedicalCondition",
"name": "Organisation et administration",
"code": {
"@type": "MedicalCode",
"code": "D009934",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N04.452"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Administration de la santé publique",
"alternateName": "Public Health Administration",
"code": {
"@type": "MedicalCode",
"code": "D011635",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Stephen Thomson",
"url": "https://questionsmedicales.fr/author/Stephen%20Thomson",
"affiliation": {
"@type": "Organization",
"name": "ANU College of Law, The Australian National University, Canberra, Australia. stephen.thomson@anu.edu.au."
}
},
{
"@type": "Person",
"name": "Muhammad Zia Ud Din",
"url": "https://questionsmedicales.fr/author/Muhammad%20Zia%20Ud%20Din",
"affiliation": {
"@type": "Organization",
"name": "School of Public Administration, Central South University, Yuelu District, Changsha, Hunan, 410017, China."
}
},
{
"@type": "Person",
"name": "Xu Yuan Yuan",
"url": "https://questionsmedicales.fr/author/Xu%20Yuan%20Yuan",
"affiliation": {
"@type": "Organization",
"name": "School of Public Administration, Central South University, Yuelu District, Changsha, Hunan, 410017, China. xuyuanyuanj@163.com."
}
},
{
"@type": "Person",
"name": "Naqib Ullah Khan",
"url": "https://questionsmedicales.fr/author/Naqib%20Ullah%20Khan",
"affiliation": {
"@type": "Organization",
"name": "School of Public Administration, Central South University, Yuelu District, Changsha, Hunan, 410017, China. naqibkhan05@csu.edu.cn."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Design of Bright Chemogenetic Reporters Based on the Combined Engineering of Fluorogenic Molecular Rotors and of the HaloTag Protein.",
"datePublished": "2024-04-04",
"url": "https://questionsmedicales.fr/article/38573546",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/chem.202400641"
}
},
{
"@type": "ScholarlyArticle",
"name": "High-Entropy Engineering of Cubic SiP with Metallic Conductivity for Fast and Durable Li-Ion Batteries.",
"datePublished": "2024-04-04",
"url": "https://questionsmedicales.fr/article/38573654",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/adma.202314054"
}
},
{
"@type": "ScholarlyArticle",
"name": "Development of a microfluidic-assisted open-source 3D bioprinting system (MOS3S) for the engineering of hierarchical tissues.",
"datePublished": "2024-04-02",
"url": "https://questionsmedicales.fr/article/38596662",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ohx.2024.e00527"
}
},
{
"@type": "ScholarlyArticle",
"name": "Recent progress in the advanced strategies, rational design, and engineering of electrocatalysts for nitrate reduction toward ammonia.",
"datePublished": "2024-04-02",
"url": "https://questionsmedicales.fr/article/38564180",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1039/d4cp00659c"
}
},
{
"@type": "ScholarlyArticle",
"name": "Enhanced gorilla troops optimizer powered by marine predator algorithm: global optimization and engineering design.",
"datePublished": "2024-04-01",
"url": "https://questionsmedicales.fr/article/38561346",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-57098-8"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Administration des services de santé",
"item": "https://questionsmedicales.fr/mesh/D006298"
},
{
"@type": "ListItem",
"position": 3,
"name": "Organisation et administration",
"item": "https://questionsmedicales.fr/mesh/D009934"
},
{
"@type": "ListItem",
"position": 4,
"name": "Administration de la santé publique",
"item": "https://questionsmedicales.fr/mesh/D011635"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Administration de la santé publique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Administration de la santé publique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Administration de la santé publique",
"description": "Comment évaluer l'efficacité d'un programme de santé publique ?\nQuels outils sont utilisés pour le diagnostic en santé publique ?",
"url": "https://questionsmedicales.fr/mesh/D011635?mesh_terms=Engineering&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Administration de la santé publique",
"description": "Quels symptômes indiquent un problème de santé publique ?\nComment les symptômes de maladies affectent-ils la santé publique ?",
"url": "https://questionsmedicales.fr/mesh/D011635?mesh_terms=Engineering&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Administration de la santé publique",
"description": "Quelles stratégies de prévention sont efficaces ?\nComment la prévention est-elle mesurée ?",
"url": "https://questionsmedicales.fr/mesh/D011635?mesh_terms=Engineering&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Administration de la santé publique",
"description": "Quels traitements sont prioritaires en santé publique ?\nComment les traitements sont-ils administrés en santé publique ?",
"url": "https://questionsmedicales.fr/mesh/D011635?mesh_terms=Engineering&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Administration de la santé publique",
"description": "Quelles complications peuvent survenir sans intervention en santé publique ?\nComment les complications affectent-elles les systèmes de santé ?",
"url": "https://questionsmedicales.fr/mesh/D011635?mesh_terms=Engineering&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Administration de la santé publique",
"description": "Quels sont les principaux facteurs de risque en santé publique ?\nComment identifier les facteurs de risque dans une population ?",
"url": "https://questionsmedicales.fr/mesh/D011635?mesh_terms=Engineering&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer l'efficacité d'un programme de santé publique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité se mesure par des indicateurs de santé, des enquêtes et des analyses de données."
}
},
{
"@type": "Question",
"name": "Quels outils sont utilisés pour le diagnostic en santé publique ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des enquêtes épidémiologiques, des statistiques de santé et des études de cohorte sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème de santé publique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des épidémies, des taux de mortalité élevés et des maladies infectieuses en hausse sont des indicateurs."
}
},
{
"@type": "Question",
"name": "Comment les symptômes de maladies affectent-ils la santé publique ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils influencent les politiques de santé, la prévention et les ressources allouées aux soins."
}
},
{
"@type": "Question",
"name": "Quelles stratégies de prévention sont efficaces ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les campagnes de vaccination, l'éducation à la santé et les politiques de santé publique sont efficaces."
}
},
{
"@type": "Question",
"name": "Comment la prévention est-elle mesurée ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est mesurée par la réduction des cas de maladies, l'augmentation des vaccinations et des dépistages."
}
},
{
"@type": "Question",
"name": "Quels traitements sont prioritaires en santé publique ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations, les traitements des maladies infectieuses et la santé maternelle sont prioritaires."
}
},
{
"@type": "Question",
"name": "Comment les traitements sont-ils administrés en santé publique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont souvent fournis par des programmes de santé communautaire et des campagnes de sensibilisation."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir sans intervention en santé publique ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des épidémies, des résistances aux antibiotiques et des maladies chroniques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles les systèmes de santé ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles augmentent la charge sur les systèmes de santé, nécessitant plus de ressources et de personnel."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque en santé publique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les comportements à risque, la pauvreté et l'accès limité aux soins sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "Comment identifier les facteurs de risque dans une population ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des études épidémiologiques, des enquêtes et des analyses de données démographiques."
}
}
]
}
]
}
The combination of fluorogenic probes (fluorogens) and self-labeling protein tags represent a promising tool for imaging biological processes with high specificity but it requires the adequation betwe...
A cost-effective, scalable ball milling process is employed to synthesize the InGeSiP3 compound with a cubic ZnS structure, aiming to address the sluggish reaction kinetics of Si-based anodes for Lith...
The engineering of new 3D bioprinting approaches has shown great promise in the field of tissue engineering and disease modelling. However, the high cost of commercial 3D bioprinters has limited their...
Ammonia is a valuable feedstock for most chemicals, pharmaceuticals, and fertilizer products. It is a promising carbon-free energy source. Under severe experimental circumstances (high temperature and...
This study presents an advanced metaheuristic approach termed the Enhanced Gorilla Troops Optimizer (EGTO), which builds upon the Marine Predators Algorithm (MPA) to enhance the search capabilities of...
In the last 30 years, there have been nearly 60, 000 publications about electrospun nanofibers, but it is still unclear whether nanoscale fibers are really necessary for electrospun tissue engineering...
To create tissue-engineered vascular grafts (TEVGs) in vitro, vascular smooth muscle cells (VSMCs) must function effectively and produce sufficient extracellular matrix (ECM) in a three-dimensional sp...
Targeted drug delivery and the reduction of off-target effects are crucial for the promising clinical application of nucleic acid drugs. To address this challenge, we developed a new approach for trea...
The varicella-zoster virus (VZV), belonging to the group of human α-herpesviruses, has yet to be developed as a platform for oncolytic virotherapy, despite indications from clinical case reports sugge...
Here, we constructed oncolytic VZV candidates based on the vaccine strain vOka and the laboratory strain Ellen. These newly engineered viruses were subsequently assessed for their oncolytic properties...
In the MeWo xenograft model, both vOka and Ellen exhibited potent antitumor efficacy. However, it was observed that introducing a hyperfusogenic mutation into glycoprotein B led to a reduction in VZV'...
These findings highlight the potential of using Ellen-ΔORF8-tet-off-scIL12 as a novel VZV-based oncolytic virotherapy....
In plants and mammals, non-homologous end-joining is the dominant pathway to repair DNA double strand breaks, making it challenging to generate knock-in events. We identified two groups of exonuclease...